AIDS Therapies

Combination Therapy Effective in Children

Published in AIDS Weekly, January 10th, 2000

An article published in the December 16, 1999, issue of The New England Journal of Medicine concluded that combination HIV therapy with DuPont Pharmaceuticals' Sustiva (efavirenz) plus nelfinavir and two nucleoside reverse transcriptase inhibitors has potent and sustained anti-viral activity in nucleoside-experienced children.

According to the article, this sustained antiviral effect "appears to be similar or superior to that reported with other regimens containing a protease inhibitor."

"These data suggest a good outcome for children receiving this therapy," said Stephen Spector, MD, chair of the Executive Committee for the Pediatric AIDS Clinical...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2000-01-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry